Cargando…

A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT

Relapse after allogeneic stem cell transplantation (allo-SCT) remains the primary cause of treatment failure. A second SCT can result in long-term survival in a subset of patients, but the relapse rate remains high. We conducted a single-center, phase 1, modified 3 + 3 dose-escalation study of the f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tran, Misha C., Hasan, Yasmin, Wang, Amy, Yenice, Kamil, Partouche, Julien, Stock, Wendy, Larson, Richard A., Kosuri, Satyajit, LaBelle, James L., Kline, Justin, Riedell, Peter A., Artz, Andrew S., Weichselbaum, Ralph, Bishop, Michael R., Aydogan, Bulent, Liu, Hongtao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2022
Materias:	Clinical Trials and Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898602/ https://www.ncbi.nlm.nih.gov/pubmed/35851593 http://dx.doi.org/10.1182/bloodadvances.2022007530

Ejemplares similares

P1318: THE IMPACT OF MELPHALAN DOSING IN COMBINATION WITH FLUDARABINE IN CLINICAL OUTCOMES OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES RECEIVING ALLO-HCT
por: Albanyan, O., et al.
Publicado: (2022)

Editorial: Strengths and Challenges of Allo-SCT in the Modern Era
por: Malagola, Michele, et al.
Publicado: (2022)

Rheumatoid arthritis: GWAS or TMI?
por: Cronstein, Bruce N
Publicado: (2009)

Knowledge-based planning for multi-isocenter VMAT total marrow irradiation
por: Ahn, Kang-Hyun, et al.
Publicado: (2022)

Relationship of iothalamate clearance and NRM in patients receiving fludarabine and melphalan reduced-intensity conditioning
por: Kutzke, Jade L., et al.
Publicado: (2022)

CD34(+) cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies
por: Holtan, S G, et al.
Publicado: (2010)

Fatal H1N1 influenza infection in an allo-SCT recipient
por: Rozovski, U, et al.
Publicado: (2010)

Collision of evidence and assumptions: TMI déjà view.
por: Wing, S, et al.
Publicado: (2000)

Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center
por: Bensinger, W, et al.
Publicado: (2012)

Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party
por: Duque-Afonso, Jesus, et al.
Publicado: (2022)

TmiRUSite and TmiROSite scripts: searching for mRNA fragments with miRNA binding sites with encoded amino acid residues
por: Berillo, Olga, et al.
Publicado: (2014)

Re: "Collision of Evidence and Assumptions: TMI Déjà View"
por: Talbott, EO, et al.
Publicado: (2000)

Outcomes of Allogeneic Stem Cell Transplant (allo-SCT) Recipients in the Era of Newer Antifungal Agents
por: Shah, Nishi, et al.
Publicado: (2014)

Reduced Intensity Allogeneic Hematopoietic Cell Transplantation using Fludarabine-Melphalan conditioning for Treatment of Mature T-cell Lymphomas
por: Delioukina, Maria, et al.
Publicado: (2011)

Comparison of graft versus host disease with three different alemtuzumab schedules in unrelated donor fludarabine and melphalan allografts
por: Green, Kile, et al.
Publicado: (2017)

Fludarabine-Melphalan-Campath, Followed by Unmanipulated Peripheral-Blood Haematopoietic Stem Cells, Can Still Cure Lymphoma
por: Avenoso, Daniele, et al.
Publicado: (2023)

Feasibility of a novel dose fractionation strategy in TMI/TMLI
por: Bao, Zhirong, et al.
Publicado: (2018)

What is known about palliative care in adult patients with allogeneic stem cell transplantation (allo-SCT)?
por: Simon, Steffen T., et al.
Publicado: (2021)

Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation
por: Duque-Afonso, Jesús, et al.
Publicado: (2020)

Rapid Recovery from Chronic PRCA by MSC Infusion in Patient after Major ABO-Mismatched alloSCT
por: Sergeevicheva, Vera, et al.
Publicado: (2012)

NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML
por: Chretien, Anne-Sophie, et al.
Publicado: (2017)

Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis
por: Landau, H, et al.
Publicado: (2017)

Can allo-SCT with RIC cure ATLL? Long-term survivors with excellent PS and with heterogenous HTLV-1 proviral load level
por: Uike, Naokuni, et al.
Publicado: (2011)

PuTmiR: A database for extracting neighboring transcription factors of human microRNAs
por: Bandyopadhyay, Sanghamitra, et al.
Publicado: (2010)

Tumor Selective Cytotoxic Action of a Thiomorpholin Hydroxamate Inhibitor (TMI-1) in Breast Cancer
por: Mezil, Lynda, et al.
Publicado: (2012)

Complete Genome Sequence of Thermus thermophilus TMY, Isolated from a Geothermal Power Plant
por: Fujino, Yasuhiro, et al.
Publicado: (2017)

Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis
por: Shen, Zhenglei, et al.
Publicado: (2018)

Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan–Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation
por: Patel, Khilna, et al.
Publicado: (2016)

Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant
por: Fan, Yun, et al.
Publicado: (2019)

Complete Genome Resequencing of Thermus thermophilus Strain TMY by Hybrid Assembly of Long- and Short-Read Sequencing Technologies
por: Miyazaki, Kentaro, et al.
Publicado: (2021)

SCT Barrel
por: Marcelloni Oliveira, C
Publicado: (2005)

SCT barrel
por: Marcelloni Oliveira, C
Publicado: (2005)

Commissioning of the SCT
por: Hayward, H
Publicado: (2008)

Single center experience with total body irradiation and melphalan (TBI-MEL) myeloablative conditioning regimen for allogeneic stem cell transplantation (SCT) in patients with refractory hematologic malignancies
por: Bhatnagar, Bhavana, et al.
Publicado: (2013)

Association of Serum Ferritin Levels Before Start of Conditioning With Mortality After alloSCT – A Prospective, Non-interventional Study of the EBMT Transplant Complications Working Party
por: Penack, Olaf, et al.
Publicado: (2020)

Total marrow irradiation (TMI): Addressing an unmet need in hematopoietic cell transplantation - a single institution experience review
por: Wong, Jeffrey Y.C., et al.
Publicado: (2022)

Frame‐based radiosurgery of multiple metastases using single‐isocenter volumetric modulated arc therapy technique
por: Ahn, Kang‐Hyun, et al.
Publicado: (2019)

P371: PONATINIB AS A PROPHYLACTIC OR PRE-EMPTIVE STRATEGY TO PREVENT CYTOLOGICAL RELAPSE AFTER ALLO-SCT IN PATIENTS WITH PH POS ALL TRANSPLANTED IN COMPLETE CYTOLOGICAL REMISSION
por: Candoni, Anna, et al.
Publicado: (2023)

Neurological illness following treatment with fludarabine.
por: Johnson, P. W., et al.
Publicado: (1994)

[(18)F]-Fludarabine for Hematological Malignancies
por: Barré, Louisa, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5gplps9s8vpoioc8i51sm7manu